Latest Capital Raises News

Barton Gold Holdings has secured $15 million through an institutional placement led by Franklin Templeton, with a $2.5 million Share Purchase Plan opening to shareholders. The capital raise supports the company’s goal to commission Stage 1 production by the end of 2026 in South Australia’s Gawler Craton.

Vulcan Energy has advanced its Phase One Lionheart Project with major German government grants, a strategic capital raise, and a significant lithium resource upgrade, positioning itself as a key player in Europe's EV battery supply chain.

Westar Resources has secured $1.5 million through a heavily discounted share placement aimed at funding exploration and new project due diligence. The capital raise involves issuing 300 million shares, including participation from company directors.

Hazer Group has made significant strides in commercialising its methane pyrolysis technology, advancing key partnerships and strengthening its intellectual property portfolio amid a tightening global graphite market.

Gateway Mining Ltd's latest surface geochemical sampling confirms an extensive 11.5km gold anomaly at its Great Western target, signalling a potentially significant new gold camp in Western Australia's Yandal Gold Project.

Patronus Resources Limited reported a significant boost in cash reserves to $7.1 million for Q3 2025, driven by strong investing activity despite ongoing operating cash outflows.

Sarama Resources has completed the third tranche of its A$2.7 million equity placement, raising A$100,000 to advance exploration at its Cosmo Gold Project and support ongoing arbitration efforts.

Sultan Resources has increased its capital raising to $1.1 million through additional investor interest, with key approvals pending at the upcoming AGM. The funds aim to accelerate exploration at its promising projects in Namibia and Western Australia.

EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

SIV Capital Limited reported a $110,000 net cash outflow for Q1 FY26, maintaining a strong cash reserve of $8.07 million despite its securities suspension by ASX since December 2024.

Austral Resources Australia has locked in $40 million through a discounted share placement, setting the stage for its ASX reinstatement and ambitious expansion in Queensland's copper belt.